

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## **Nucleosides, Nucleotides and Nucleic Acids**

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

## **Anti-Inflammatory Activity of Purine Nucleoside Analogs**

Stephanie A. Hartsel<sup>a</sup>; Cecil Chen<sup>a</sup>; John Kennedy<sup>a</sup>; Allison Bendele<sup>a</sup>; Cliff Wright<sup>a</sup>; William S. Marshall<sup>a</sup>

<sup>a</sup> Amgen Inc., Colorado

**To cite this Article** Hartsel, Stephanie A. , Chen, Cecil , Kennedy, John , Bendele, Allison , Wright, Cliff and Marshall, William S.(1997) 'Anti-Inflammatory Activity of Purine Nucleoside Analogs', *Nucleosides, Nucleotides and Nucleic Acids*, 16: 7, 1291 – 1294

**To link to this Article:** DOI: 10.1080/07328319708006173

**URL:** <http://dx.doi.org/10.1080/07328319708006173>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## ANTI-INFLAMMATORY ACTIVITY OF PURINE NUCLEOSIDE ANALOGS

Stephanie A. Hartsel , Cecil Chen, John Kennedy, Allison Bendele, Cliff Wright and William S. Marshall  
Amgen Inc., Colorado, 80301

### ABSTRACT


It is well known that adenosine plays an important role in inflammatory processes. A collection of adenosine analogs modified in the base and/or sugar functional moiety have been synthesized and submitted for biological testing. Each purine nucleoside analog was tested for inhibition of endothelial cell activation by various inflammatory stimuli. A number of analogs exhibited potent anti-inflammatory activity. Animal studies have been carried out on AMG002370 which was found to potently inhibit adjuvant induced arthritis in the Lewis rat.

### INTRODUCTION


A collection of adenosine analogs have been examined for their ability to inhibit cytokine (IL-8) production from human umbilical vein endothelial cells (HUVEC) induced by various inflammatory stimuli. AMG002370 (Figure I) significantly inhibited ( $IC_{50} = 0.5\mu M$ ) both  $TNF\alpha$  and LPS stimulated IL-8 production while having no effect on cell viability at concentrations up to  $100\mu M$  (Figure II). In addition, AMG002370 was found to inhibit the  $TNF\alpha$ -induced expression of E-selectin, vascular cell adhesion molecule-1 (VCAM-1), and intercellular adhesion molecule-1 (ICAM-1) in a dose dependent fashion. Interestingly, AMG002370 does not effect the  $TNF\alpha$ -induced activation of the transcription factor NF- $\kappa B$ , an important regulator of adhesion molecule gene expression. In an effort to unveil important structure activity relationships and help determine the biochemical mechanism of action, over thirty-five analogs modified in the base and/or sugar moiety were synthesized and tested.

Studies have shown that the activity of AMG002370 is dependent on nucleoside transport. S-(p-nitrobenzyl)-6-thioinosine is a potent inhibitor of nucleoside transport, but has little effect on membrane signalling events. AMG002370 is inactive when S-(p-nitrobenzyl)-6-thioinosine is present (data not shown). The blockade of AMG002370 by this nucleoside transport inhibitor indicates that cellular uptake is crucial for inhibitory effects.

AMG002370 had no effect on NF- $\kappa B$  activation and I $\kappa B$ - $\alpha$  degradation in  $TNF\alpha$  - stimulated cells (data not shown). Numerous studies have demonstrated that NF- $\kappa B$  is required for cytokine- and endotoxin-induced expression of CAM genes (E-selectin, VCAM-1 and ICAM-1)<sup>1</sup>. Treatment of HUVEC with  $TNF\alpha$  resulted in rapid appearance of NF- $\kappa B$ /DNA-binding activity. Pretreatment of HUVEC with adenosine ( $10\mu M$ ) prior to  $TNF\alpha$  stimulation had no effect on this activity. Interestingly, AMG002370 ( $10\mu M$ ) also had no effect on NF- $\kappa B$  activation in  $TNF\alpha$ -stimulated HUVEC. In HUVEC, the  $TNF\alpha$ -induced appearance of nuclear NF- $\kappa B$ /DNA-binding coincides with the disappearance of I $\kappa B$ - $\alpha$ . Activation of HUVEC with  $TNF\alpha$  results in the complete loss of I $\kappa B$ - $\alpha$  from cytoplasm. Pretreatment of HUVEC with either adenosine ( $10\mu M$ ) or AMG002370 ( $10\mu M$ ) did not prevent the  $TNF\alpha$ -induced degradation of I $\kappa B$ - $\alpha$ . (data not shown).



AMG002370


**Figure I**

AMG002370 INHIBITION OF IL-8 PRODUCTION FROM HUVECS  
IN RESPONSE TO TNF $\alpha$  (0.01 $\mu$ g/ml) AND LPS (0.1 $\mu$ g/ml) STIMULI

**Figure II**

The data shown in Figure II was obtained as follows. AMG002370 and adenosine were added to HUVECs. Endothelial basal media (EMB) was added to unstimulated and stimulated controls. The stimuli is added ( TNF- $\alpha$  or LPS ) at 10X concentration to each sample excluding the unstimulated control. After incubation the samples were centrifuged and the supernatant was isolated for IL-8 determination.

**Effect of AMG002370 or Adenosine on the Expression of Adhesion Molecules by TNF-Stimulated HUVEC**



**Figure III**

**Inhibition of TNF $\alpha$ -induced cell surface expression of E-selectin, VCAM-1, ICAM-1 and ICAM-2 by AMG002370 in endothelial cells.**

HUVEC monolayers in 96-well plates were either left untreated or pretreated with various concentration of AMG002370 (A) or adenosine (B) for 30-60 minutes before stimulation with TNF $\alpha$  (10 ng/ml). Test and control samples were performed in triplicate in each experiment. The degree of specific antibody binding was calculated by subtracting the mean negative control value from each test value, and results were expressed as a percentage of the TNF $\alpha$ -treated control values. In all cases, observed SD were less than 5% of mean values. Data from a single experiment are shown, which are representative of four similar experiments.

## CONCLUSION

By randomly screening several existing intermediates used in nucleic acid analog synthesis, a potent inhibitor of TNF signaling in endothelial cells was identified. The high nanomolar activity of this compound in a cell culture assay led to a preliminary animal model evaluation. Although animal studies demonstrated efficacy, weight loss was observed as well as other potential toxicity. In addition, the potential interference with several important cellular processes as well as the metabolic instability of this class of compounds limits their therapeutic utility. Perhaps the most interesting result of this study is the identification of a novel mechanism of inhibition of TNF and LPS signaling in endothelial cells that appears to be independent of NF- $\kappa$ B activation.

## REFERENCE

- <sup>1</sup> Collins, T., Palmer, H.J., Whitley, M.Z., Neish, A.S., and Williams, A.J., *Trends Card. Med* 1993 3 (92)